This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ioannou, Y. Articles by Isenberg, D. A Search for Related Content PubMed PubMed Citation Articles by Ioannou, Y. Articles by Isenberg, D. A Social Bookmarking                         What's this?

Immunisation of patients with systemic lupus erythematosus: the current state of play

David A Isenberg

Centre for Rheumatology/Bloomsbury Rheumatology Unit, Department of Medicine, University College London, London,UK

Concerns regarding the safety and efficacy of immunisation in patients with SLE have persisted for over 50 y and indeed infection remains a leading cause of morbidity and mortality in these patients. There have been many anecdotal reports in the literature linking vaccination with either induction or exacerbation of SLE disease. However prospective studies have shown that immunisation with inactivated/killed vaccines is probably safe in patients with SLE. Individuals on immunosuppressive agents and/or high dose steroid (more than 20 mg/d) should not receive live vaccines, as stated in guidelines proposed by the British Society of Rheumatology. The safety of hepatitis B vaccination in patients with SLE is as yet undetermined and a prospective study is required. However until such evidence becomes available the advice of the BSR should be followed and patients with SLE who are at risk of exposure should be vaccinated.

It remains uncertain whether the immune response to immunisation is significantly impaired by active disease and/or immunosuppressive treatment and to what extent. Most patients do however seem to mount a satisfactory immune response though this may not be quantitatively and qualitatively the same as healthy controls.

Key Words: immunisation • SLE • vaccination • vaccine safety • vaccine efficacy

Lupus, Vol. 8, No. 7, 497-501 (1999)
DOI: 10.1191/096120399678840855


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K.A.M. Kuruma, E.F. Borba, M.H. Lopes, J.F. de Carvalho, and E. Bonfa Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus Lupus, May 1, 2007; 16(5): 350 - 354. [Abstract] [PDF]

				A Holvast, A Huckriede, J Wilschut, G Horst, J J C De Vries, C A Benne, C G M Kallenberg, and M Bijl Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease Ann Rheum Dis, July 1, 2006; 65(7): 913 - 918. [Abstract] [Full Text] [PDF]

				Y Ioannou and D A Isenberg Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge Postgrad. Med. J., October 1, 2002; 78(924): 599 - 606. [Abstract] [Full Text] [PDF]

				A Aron-Maor and Y Shoenfeld Vaccination and systemic lupus erythematosus: the bidirectional dilemmas Lupus, March 1, 2001; 10(3): 237 - 240. [Abstract] [PDF]